Literature DB >> 32410506

Baseline quality of life is associated with survival among people with advanced lung cancer.

Mario J Trejo1, Melanie L Bell1, Haryana M Dhillon2, Janette L Vardy2,3,4.   

Abstract

INTRODUCTION: Lung cancer patients presenting with advanced cancer face low survival rates and a high symptom burden. There have been mixed findings for the association between survival and various patient reported outcomes (PROs).
METHODS: We used prospective data from 111 lung cancer patients with advanced stage III/IV disease to investigate the association of survival with PROs (European Organization for Research and Treatment of Cancer Core-30 and Lung Module). Cox proportional hazard models were used to examine the individual association between several PRO measures and survival.
RESULTS: Pain in chest and global quality of life (QoL) were found to have the strongest association with survival with a 20% increased hazard of death per 10% increase in pain in chest and 14% decrease in hazard of death per 10% increase in global QoL.
CONCLUSION: Our results provide more evidence for the value of PRO data to inform clinical and patient decision-making.

Entities:  

Keywords:  Lung cancer; oncology; quality of life; survival; symptoms

Mesh:

Year:  2020        PMID: 32410506     DOI: 10.1080/07347332.2020.1765065

Source DB:  PubMed          Journal:  J Psychosoc Oncol        ISSN: 0734-7332


  2 in total

Review 1.  Cancer Chemotherapy Related Cognitive Impairment and the Impact of the Alzheimer's Disease Risk Factor APOE.

Authors:  Harvey R Fernandez; Ashima Varma; Sarah A Flowers; George William Rebeck
Journal:  Cancers (Basel)       Date:  2020-12-19       Impact factor: 6.639

2.  The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy.

Authors:  Sarah Badaoui; Adel Shahnam; Michael J Sorich; Ashley M Hopkins; Ross A McKinnon; Ahmad Y Abuhelwa
Journal:  Transl Lung Cancer Res       Date:  2022-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.